{"name":"Bio-Techne","slug":"bio-techne","ticker":"TECH","exchange":"NASDAQ","domain":"bio-techne.com","description":"Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.","hq":"Minneapolis, MN, USA","founded":1981,"employees":"3100","ceo":"Kim Kelderman","sector":"Proteins & Reagents / Diagnostics","stockPrice":44.53,"stockChange":-0.36,"stockChangePercent":-0.8,"marketCap":"$7.0B","metrics":{"revenue":1219635000,"revenueGrowth":-1.5,"grossMargin":66.4,"rdSpend":0,"netIncome":73400000,"cash":214114000,"dividendYield":0.71,"peRatio":63.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Bio-Techne Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Bio-Techne reported fourth quarter and full year 2023 financial results, with revenue increasing 14% year-over-year to $1.1 billion.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Bio-Techne Acquires ProteinSimple","summary":"Bio-Techne acquired ProteinSimple, a leading provider of protein analysis solutions, for $250 million.","drugName":"","sentiment":"positive"},{"date":"2023-09-07","type":"regulatory","headline":"Bio-Techne Receives CE Mark for Its Luminex xMAP Technology","summary":"Bio-Techne received CE mark for its Luminex xMAP technology, which enables the simultaneous analysis of multiple biomarkers in a single sample.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"pipeline","source":"simplywall.st","summary":"How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story - simplywall.st","headline":"How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"simplywall.st","summary":"Bio-Techne’s New COMET Spatial Tools Might Change The Case For Investing In Bio-Techne (TECH) - simplywall.st","headline":"Bio-Techne’s New COMET Spatial Tools Might Change The Case For Investing In Bio-Techne (TECH)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Revisit Bio-Techne (TECH) After Recent Share Price Weakness? - simplywall.st","headline":"Is It Time To Revisit Bio-Techne (TECH) After Recent Share Price Weakness?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-16","type":"earnings","source":"simplywall.st","summary":"Bio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest - simplywall.st","headline":"Bio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNRjVhbmRvdzZjbG1VMGhWYXNZaW1BYS1aVFJrM1RINDNOWnJobEszQ08zZms5eTdWS2hvbUlFeHc4ZjRPTk9fWFhfU2RlWW1rYkptLWlQUWdPc0s1dU5ydnRoV0Vyb0hyalYwM0dyNVJCb1dhd0JXSmZxazFRU1h0ZmlYZ2hrTFpv?oc=5","date":"2026-03-13","type":"earnings","source":"Yahoo Finance","summary":"Assessing Bio‑Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push - Yahoo Finance","headline":"Assessing Bio‑Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push","sentiment":"positive"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPWHVoMTN1V3hZbldnbHNHNTVhTENnYlpXMUNVODhwTVdmZGxJLWJ5N2Fka3lRbTctT1JBSzlCNzFweUlPMFNHUWg1b0JvSEJMWmhJZGVFSkd6Z1JwLU8xdnZGdTZfakdJaEpkeU1Kc21iaFJnYWlvQWk1R1RwWlpzZ1QwbVNEYnhIM1pocmhKOE1xREphZFliUjhDQTBRRTAtUkNTNDN6SVJXcnJITlB5ZVZ3NzJsdVoxaFdJZ3R4a1E5S211SmJIV01jY1ZIdVdsRG02cg?oc=5","date":"2026-02-04","type":"earnings","source":"StockStory","summary":"TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets - StockStory","headline":"TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets","sentiment":"neutral"},{"date":"2026-02-04","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQdzlmdjVKclhwOGswZEw2anZyMnZTZTRfNm9xVlZaMWtfdEFBdXRMNFBqVllBQXVXMHV6NThLRElxS2ZRbWN0dEJfZzZiUzEyQ2o3dXhNU29pZHFfRFpXc0JDYTVOd2V4ZHVmc2ZMVV9SVXJYMzkzOFJNNGZVdVVtZlFzMmhLTXNZdFpQOTRGcW1uR2ZwQ21vMDl0UmwxSklYU0VTY1pYSWdYNzV1RkJ1S3IyZlV0MlIwdlBaaFFaSmR0c2VuT1ZMNzJvQ21uNjhLcG1LSUVoYmFMek16QUxFbTJMTHZ3OVZBM3JGZ3RhX2xjeUhKcVYyeHZ6cGRJY1g3TzM0Y0tvUHludFBq?oc=5","date":"2025-12-11","type":"deal","source":"PR Newswire","summary":"Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology - PR Newswire","headline":"Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Bio","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPdkhtVVNpT0VLbFN3MGpxTXhfMjRSRUJpUEhTVmt1c0NSVzVHRVZZUXpPTERSRTZmVjBOM0tlekJ1ckp6WGd4blNrN1Z6OXplUWNlMVVyVEhGbWJBTDRYTGNBMTcxNmdHeklGTV9DdXJfU2ZhQ0lRZ1dhaVZSZGhRbkFoTQ?oc=5","date":"2025-09-15","type":"pipeline","source":"Yahoo Finance","summary":"Here’s Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne’s (TECH) Long-Term Growth Profile - Yahoo Finance","headline":"Here’s Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne’s (TECH) Long-Term Growth Profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5kSkNBdFhCUnF3eV93YTZOeTZ1U3hFZUFqRmpiVVMyOWtLM2FYRWFEWThSbHEtUGpnV0MxeWdqWEw3Wlppb1RlamVIVkREOVFUbUYtemNxLU9GZnZhbTlSQjlUV1Q3eVRWS0hWQWhFVnZWVW1sZ3NHVW1qZw?oc=5","date":"2025-09-10","type":"pipeline","source":"Yahoo Finance","summary":"Why Bio-Techne (TECH) Stock Is Down Today - Yahoo Finance","headline":"Why Bio-Techne (TECH) Stock Is Down Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOQ0kxTkVtVkFKZVQwTzBpb1BPbWpuMTgyQWZWNncwM3diSmVvS2lpZGprcEhFTTRvaFAwWmpXcEFLN1AxeXVRdXNORHNwcHRsdTh6TDlIczNha0dBSkh3RTN6QVR5OFd2X2J3WVhmc3E0ZTdHcTg0NEpUSExBRll3Rmc3ekhIb2hkblVKNFF3ZmF5NnRxTEk2Wm1HUm5IUlJMR1Z4MC1QbFR2dlpZMlhmNU9mb2ZSaVdJS3NIM192aWxUcnpyLWU2UW0yZmtwdXBSdHFyTg?oc=5","date":"2025-08-12","type":"earnings","source":"StockStory","summary":"The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call - StockStory","headline":"The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermo Fisher Scientific","Agilent Technologies","Danaher Corporation"],"therapeuticFocus":["Protein Analysis","Cell Culture","Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":1219635000,"revenuePeriod":"2025-06-30","revenueHistory":[{"value":1219635000,"period":"2025-06-30"},{"value":1159060000,"period":"2024-06-30"},{"value":1136702000,"period":"2023-06-30"}],"grossProfit":790272000,"grossProfitHistory":[{"period":"2025-06-30","value":790272000},{"period":"2024-06-30","value":769725000},{"period":"2023-06-30","value":769815000},{"period":"2022-06-30","value":756496000}],"rdSpend":99496000,"rdSpendHistory":[{"period":"2025-06-30","value":99496000},{"period":"2024-06-30","value":96664000},{"period":"2023-06-30","value":92493000},{"period":"2022-06-30","value":87140000}],"sgaSpend":415097000,"operatingIncome":242804000,"operatingIncomeHistory":[{"period":"2025-06-30","value":242804000},{"period":"2024-06-30","value":246401000},{"period":"2023-06-30","value":290998000},{"period":"2022-06-30","value":295828000}],"netIncome":73400000,"netIncomeHistory":[{"period":"2025-06-30","value":73400000},{"period":"2024-06-30","value":168105000},{"period":"2023-06-30","value":285263000},{"period":"2022-06-30","value":272051000}],"eps":0.46,"epsHistory":[{"period":"2025-06-30","value":0.46},{"period":"2024-06-30","value":1.05},{"period":"2023-06-30","value":1.76},{"period":"2022-06-30","value":1.6575}],"cash":162186000,"cashHistory":[{"period":"2025-06-30","value":162186000},{"period":"2024-06-30","value":151791000},{"period":"2023-06-30","value":180571000},{"period":"2022-06-30","value":172567000}],"totalAssets":2557868000,"totalLiabilities":639060000,"totalDebt":444058000,"equity":1918808000,"operatingCashflow":287556000,"operatingCashflowHistory":[{"period":"2025-06-30","value":287556000},{"period":"2024-06-30","value":298981000},{"period":"2023-06-30","value":254393000},{"period":"2022-06-30","value":325272000}],"capex":-31006000,"capexHistory":[{"period":"2025-06-30","value":-31006000},{"period":"2024-06-30","value":-62877000},{"period":"2023-06-30","value":-38244000},{"period":"2022-06-30","value":-44908000}],"freeCashflow":256550000,"dividendsPaid":-50391000,"buybacks":-275731000,"employees":3100,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":0.33,"netIncome":null,"rdExpense":null,"epsDiluted":0.32,"grossProfit":null,"operatingIncome":null},{"sga":113691000,"ebit":52955000,"ebitda":77664000,"period":"2025-12-31","revenue":295877000,"epsBasic":0.24,"netIncome":38009000,"rdExpense":23125000,"epsDiluted":0.24,"grossProfit":191277000,"operatingIncome":54461000},{"sga":116213000,"ebit":50925000,"ebitda":75265000,"period":"2025-09-30","revenue":286555000,"epsBasic":0.25,"netIncome":38185000,"rdExpense":24241000,"epsDiluted":0.24,"grossProfit":188112000,"operatingIncome":47658000},{"sga":23216000,"ebit":-20681000,"ebitda":6430000,"period":"2025-06-30","revenue":316964000,"epsBasic":-0.11,"netIncome":-17678000,"rdExpense":26032000,"epsDiluted":-0.11,"grossProfit":198812000,"operatingIncome":116689000},{"sga":151269000,"ebit":40281000,"ebitda":67852000,"period":"2025-03-31","revenue":316181000,"epsBasic":0.14,"netIncome":22588000,"rdExpense":24579000,"epsDiluted":0.14,"grossProfit":214556000,"operatingIncome":38708000},{"sga":121451000,"ebit":45024000,"ebitda":72108000,"period":"2024-12-31","revenue":297031000,"epsBasic":null,"netIncome":34890000,"rdExpense":25016000,"epsDiluted":null,"grossProfit":193886000,"operatingIncome":47419000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":44.53,"previousClose":44.89,"fiftyTwoWeekHigh":72.16,"fiftyTwoWeekLow":44.12,"fiftyTwoWeekRange":"44.12 - 72.16","fiftyDayAverage":53.52,"twoHundredDayAverage":57.92,"beta":1.41,"enterpriseValue":7104579072,"forwardPE":21.5,"priceToBook":3.45,"priceToSales":5.76,"enterpriseToRevenue":5.87,"enterpriseToEbitda":19.41,"pegRatio":0.65,"ebitda":366044992,"ebitdaMargin":30.2,"freeCashflow":299849376,"operatingCashflow":294857984,"totalDebt":290321984,"debtToEquity":13.9,"currentRatio":4.49,"returnOnAssets":7.5,"returnOnEquity":5.3,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":62.64,"targetHighPrice":76,"targetLowPrice":49,"dividendRate":0.32,"payoutRatio":0.46,"fiveYearAvgDividendYield":0.43,"exDividendDate":1779062400,"insiderHeldPercent":0.3,"institutionHeldPercent":116.4,"sharesOutstanding":156568751,"floatShares":154661744,"sharesShort":13338470,"shortRatio":6.6,"shortPercentOfFloat":8.5,"epsTrailing":0.7,"epsForward":2.07,"revenuePerShare":7.77,"bookValue":12.9,"officers":[{"age":57,"name":"Mr. Kim  Kelderman","title":"CEO, President & Director"},{"age":54,"name":"Mr. James T. Hippel CPA","title":"Executive VP of Finance & CFO"},{"age":50,"name":"Mr. Shane  Bohnen","title":"Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer"},{"age":56,"name":"Mr. William A. Geist","title":"President of Protein Sciences Segment"},{"age":null,"name":"Dr. Gary J. Latham Ph.D.","title":"VP & CTO"},{"age":null,"name":"Mr. David  Clair C.F.A.","title":"VP of Investor Relations & Corporate Development"},{"age":null,"name":"Mr. Gerry  Andros","title":"Vice President of Sales and Marketing"},{"age":null,"name":"Mr. Martin  Wirtz","title":"Senior Vice President of Strategy & Corporate Development"}],"industry":"Biotechnology","irWebsite":"http://www.techne-corp.com/","website":"https://www.bio-techne.com","phone":"612 379 8854"}}